Indexing
All Issues
Submission
Author Guidelines
Reviewers
Editorial Members
Publication Fee
Vol.2 , No. 1, Publication Date: Dec. 19, 2014, Page: 27-32
 in Usmanu Danfodiyo University Teaching Hospital Sokoto, North Western Nigeria&description=Treatment of HIV/AIDS patients, with HAART is the common practice in most of our health institutions, and the effect of this drug on anemia, leucopenia and thrombocytopenia in this group of patients has not been fully studied in our locality. With the wide spread side effect associated with HAART drugs, there is need to evaluate the role of HAART as it affect hematological indices. Using haematocrit centrifuge method, Burker and haemocytometer method, Packed cell volume (PCV), Total leucocyte count (TLC) and platelet count (PLC) were evaluated and the values obtained in HIV/AIDS patients not on HAART and HIV/AIDS patients on HAART were compared with apparently healthy controls. The result indicated that the mean PCV values of 38.300±4.547%, 32.467±7.133% and 34.263±7.668%, TLC, 6.360±1.567×109/L, 3.423±1.657×109/L and 3.501±1.132 ×109/L, PLC, 253.33±65.090 ×109/L, 207.37±74.65×109/L and 216.95±73.92×109/L in controls, HIV/AIDS patients not on HAART and in HIV patients on HAART treatment respectively. There were statistically significant difference (P< 0.05), between HIV patients on HAART and the controls. However there were no statistically significant difference (P>0.05) between the HIV positive on HAART and HIV positive not on HAART. However, the report from the laboratory analysis of the blood sample showed that HAART therapy increased PCV, TLC, and PLC cell count of the subjects. Therefore, we concluded that, HAART treatment from these studies has the capability of reducing the incidence of anemia, lymphopoenia and thrombocytopenia which are associated with HIV/AIDS disease progression and death in infected patients. Total lymphocyte count, Packed Cell Volume and platelet count could also serve as useful predictive tools in the management and monitoring of HIV/AIDS infected patients in resource limited settings.&picture=http://www.aascit.org/aascit/decorators/img/journal/902.jpg)
| [1] | Yakubu Abdulrahaman, Haematology Department, Faculty of Medical Laboratory Science, Usmanu Danfodiyo University, Sokoto, Nigeria. |
| [2] | Mohammed Haruna Yeldu, Chemical Pathology Department, Faculty of Medical Laboratory Science, Usmanu Danfodiyo University, Sokoto, Nigeria. |
| [3] | Isaac Isah Zama, Haematology Department, Faculty of Medical Laboratory Science, Usmanu Danfodiyo University, Sokoto, Nigeria. |
| [4] | Aminu Amina, Haematology Department, Faculty of Medical Laboratory Science, Usmanu Danfodiyo University, Sokoto, Nigeria. |
Treatment of HIV/AIDS patients, with HAART is the common practice in most of our health institutions, and the effect of this drug on anemia, leucopenia and thrombocytopenia in this group of patients has not been fully studied in our locality. With the wide spread side effect associated with HAART drugs, there is need to evaluate the role of HAART as it affect hematological indices. Using haematocrit centrifuge method, Burker and haemocytometer method, Packed cell volume (PCV), Total leucocyte count (TLC) and platelet count (PLC) were evaluated and the values obtained in HIV/AIDS patients not on HAART and HIV/AIDS patients on HAART were compared with apparently healthy controls. The result indicated that the mean PCV values of 38.300±4.547%, 32.467±7.133% and 34.263±7.668%, TLC, 6.360±1.567×109/L, 3.423±1.657×109/L and 3.501±1.132 ×109/L, PLC, 253.33±65.090 ×109/L, 207.37±74.65×109/L and 216.95±73.92×109/L in controls, HIV/AIDS patients not on HAART and in HIV patients on HAART treatment respectively. There were statistically significant difference (P< 0.05), between HIV patients on HAART and the controls. However there were no statistically significant difference (P>0.05) between the HIV positive on HAART and HIV positive not on HAART. However, the report from the laboratory analysis of the blood sample showed that HAART therapy increased PCV, TLC, and PLC cell count of the subjects. Therefore, we concluded that, HAART treatment from these studies has the capability of reducing the incidence of anemia, lymphopoenia and thrombocytopenia which are associated with HIV/AIDS disease progression and death in infected patients. Total lymphocyte count, Packed Cell Volume and platelet count could also serve as useful predictive tools in the management and monitoring of HIV/AIDS infected patients in resource limited settings.
Keywords
PCV, TLC, PLC, HIV and HAART Treatment
Reference
| [01] | Lloyed A. HIV infection and AIDS (Review). Papua New Guinea Med. J. 1996; 39: 174-188 |
| [02] | James T, Rebecca B, Heiner G, Philippe M, Frank M. HIV-associated Adult Mortality in a Rural Tanzanian Population. Official J. Int. Soc. AIDS. 1997; 11: 801-807. |
| [03] | Kelly P. Diarrhoea and AIDS Recent Development in the African Setting. Afr. Health. 1998; 20: 16-18 |
| [04] | Okolie MN, Eghafona NO, Omoregie R. Anti-human Immunodeficiency Virus Agents. J Med. Lab. Sci. 2003; 12:1–14. |
| [05] | Coyle TE. Hematologic complications of human immunodeficiency virus infection and the acquired immunodeficiency syndrome. Med Clin North Am. 1997; 81(2):449–470. |
| [06] | Cosby CD. Hematologic disorders associated with human immunodeficiency virus and AIDS. J Infus Nurs. 2007; 30(1):22–32 |
| [07] | Moyle G. Anaemia in persons with HIV infection: prognostic marker and contributor tomorbidity. AIDS Rev. 2002; 4(1):13–20. |
| [08] | Volberding P. The impact of anemia on quality of life in human immunodeficiency virus-infected patients. J Infect Dis. 2002; 185(Suppl 2):S110–S114. |
| [09] | Odunukwe N, Idigbe O, Kanki P, Adewole T, Onwujekwe D, Audu R, Onyewuche J. Haematological and biochemical response to treatment of HIV-1 infection with a combination of nevirapine + stavudine + lamivudine in Lagos, Nigeria. Turkish J Haem. 2005;22:125–131 |
| [10] | WHO, 2003. Scaling up Retroviral Therapy in Resource Limited Setting. World Health Organisation, Rome. |
| [11] | Gea-Banacloche JC, Lane HC. Immune reconstitution in HIV-1 infections. AIDS. 1999; 13:525–538. |
| [12] | Omoregie R, Egbeobauwaye A, Ogefere H, Omokaro EU, Ekeh CC. Prevalence of Antibodies to HAART Agents among HIV Patients in Benin city, Nigeria. Afri J. Biomed Res. 2008; 11:33–37. |
| [13] | Kovacs JA, Deyton L, Davey R, Falloon J Zunich K. Combined Zidovudine and interferon-alpha therapy in patients with Kaposi sarcoma and the acquired immunodeficiency syndrome (AIDS). Ann Int. Med. 1989; 111: 280-287. |
| [14] | Graham NM, Zeger SL, Park LP, Vermund SH, Detels R, Rinaldo CR Phair JP. The effects of survival of early treatment of human immunodeficiency virus infection. N. E. J. Med. 1992; 326: 1037-1042. |
| [15] | Chow Y, Merrill D. Use of evolutionary limitations of HIV-1 multi-drug resistance of optimize therapy. Nature, 1993; 361: 650-654. |
| [16] | Servais J, Nkoghe D, Schmit JC, Arendt V, Robert I, Staub T, Moutschen M, Schneider F, Hemmer R: HIV-associated hematologic disorders are correlated with plasma viral load and improve under highly active antiretroviral therapy. J Acquir Imm Defic Syndr 2001,28(3):221–225 |
| [17] | Gea-Banacloche JC, Lane HC. Immune reconstitution in HIV-1 infections. AIDS. 1999; 13:525–538. |
| [18] | Glatt AE, Anand A. Thrombocytopenia in patients infected with human immunodeficiency virus: treatment update. Clin Infect Dis. 1995;21:415-423 |
| [19] | Ballem PJ, et al. Kinetic studies of the mechanism of thrombocytopenia in patients with human immunodeficiency virus infection. N Engl J Med 1992;327:1779-1784 |
| [20] | Maness LJ, Blair DC, Newman N, Coyle TE. Elevation of platelet counts associated with indinavir treatment in human immunodeficiency virus-infected patients. Clin Infect Dis. 1998;26:207-208 |
| [21] | Mosier DE. HIV results in the frame CD4+ cell turnover. Nature, 1995; 375: 193-194. |
| [22] | Dimitrov DS, Martin MA, HIV results in the frame CD4+ cell turnover. Nature, 1995; 375: 194-195. |
| [23] | Grossman Z, Herberman RB. T-cell homeostasis in HIV infection is neither failing nor blind: Modified cell counts reflect an adaptive response of the host. Nat. Med. 1997; 3: 486-490. |
| [24] | Iornon TF, John K, Nyitor AS, Terzungwe A. Antiretroviral drug therapy in Benue state, Nigeria a follow up of 20PLWA in private Hosipital in Gboko. J. Hum. Ecol., 2008; 23: 267-273. |
| [25] | Minzi OM, Irunde H, Moshiro C. HIV patients presenting common adverse drug events caused by highly active antiretroviral therapy in Tanzania. Tanz J Health Res. 2009 Jan 11(1):5–10 |
| [26] | Baker K. The hematologic complications of HIV infection. ASH Education Program 2003;1:299 |
| [27] | Moore RD, Keruly JC, Chaisson RE. Anemia and survival in HIV infection. J Acquir Imm Defic Syndr Hum Retrovirol. 1998;19(1):29–33. |
| [28] | Mocroft A, Kirk O, Barton SE, Dietrich M, Proenca R, Colebunders R, Pradier C, dArminio Monforte A, Ledergerber B, Lundgren JD. Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. EuroSIDA study group. AIDS. 1999; 13(8):943–950. |
| [29] | Levine AM, Berhane K, Masri-Lavine L, Sanchez M, Young M, Augenbraun M, Cohen M, Anastos K, Newman M, Gange SJ, Watts H. Prevalence and correlates of anemia in a large cohort of HIV-infected women: Women's Interagency HIV Study. J Acquir Immune Defic Syndr. 2001; 26(1):28–35. |
| [30] | Belperio PS, Rhew DC. Prevalence and outcomes of anemia in individuals with human immunodeficiency virus: a systematic review of the literature. Am J Med. 2004; 116(Suppl 7A):27S–43S. |
| [31] | Abrams DI, Steinhart C, Frascino R. Epoetin alfa therapy for anaemia in HIV-infected patients: impact on quality of life. Int J STD AIDS. 2000;11(10):659–665. |
| [32] | Blockman D. HIV related thrombocytopenia. Br. J. Haematol. 1991; 99: 350-354 |
| [33] | Chukwurah FE, Echeobi D, Nneli RO, Haematological profile of human immunodeficient (HIV) seropositive patients on antiretroviral (ARV) therapy: Implication of nutrition. Res. J. Med. Sci., 2007; 1: 242-244. |
| [34] | Attili SVS, Singh VP, Rai M, Varma DV, Gulati AK, Sundar S. Hematological profile of HIV patients in relation to immune status - a hospital-based cohort from Varanasi, North India. Turk Journal of Hematology. 2008;25(1) |
| [35] | Pechere M, Samii K, Hirschel B. HIV-related thrombocytopenia. N Engl J Med. 1993; 328(24):1785–1786. |
| [36] | Martinez G, Gonzalez I, Tarinas A, Alvarez A, Giuliani A, Molina R, Tapanes R, Perez J, Leon OS. Contribution to characterization of oxidative stress in HIV/AIDS patients. Pharmacol Res. 2003; 47(3):217–224. |
| [37] | Amballi AA, Ajibola A, Ogun SA, Ogunkolo OF, Salu LO, Oritogun KS, et al. Demographic pattern and haematological profile in people living with HIV/AIDS in a university teaching hospital. Sci Res Essay 2007; 2: 315-8. |
| [38] | Baker et al. HIV-related immune suppression after ART predicts risk of non-opportunistic diseases: Results from the FIRST study. Proceedings of the 14th Conference on Retroviruses and Opportunistic Infections. 2007; 25-28, Los Angeles, pp: 1-2. |
| [39] | Mohri H, Bonhoeffer S, Monard S, Perelson AS, Ho DD, Rapid turnover of T lymphocytes in SIV-infected rhesus macaques. Science, 1998; 279: 1223-1227. |
| [40] | WKBA O, Quaye, L Amidu, N and Addai-M.O. 2011 Prevalence of anaemia and immunological markers among Ghanaian HAART-naïve HIV-patients and those on HAART. Afr Health Sci. 11(1): 2–15. |
| [41] | Haematocrite centrifuge method recommended by WHO 2000 |
| [42] | BRAND® counting chamber BLAUBRAND®Bürker pattern |
| [43] | Becton-Dickinson. Unopette WBC/Platelet determination for manual methods. |
